Inhibitory mechanism of human platelet aggregation by nafamostat mesilate

Platelets

Volumn 10, Issue 4, 1999, Pages 212-218

  Fuse, Ichiro ^a   Higuchi, Wataru ^a   Toba, Ken ^a   Aizawa, Yoshifusa ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDIC ACID; CALCIMYCIN; CALCIUM; CELL SURFACE PROTEIN; COLLAGEN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FIBRINOGEN RECEPTOR; FLUORIDE SODIUM; NAFAMSTAT MESILATE; PHORBOL 13 ACETATE 12 MYRISTATE; THROMBIN; THROMBIN RECEPTOR; THROMBOXANE A2; THROMBOXANE B2;

AGONIST; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0032798245     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109976040     Document Type: Article

References (20)

1. 1. Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, Suzuki S, Fujita M, Pharmacological studies of FUT-175, nafamostat mesilate. I. Inhibition of protease activity in in vivo and in vitro experiments. Jpn J Pharmacol 1984; 35: 203-27.
2. 2. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, Aoyama T. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol 1986; 41: 155-62.
3. 3. Yoshikawa T, Murakami M, Furukawa Y, Kato H, Takemura S, Kondo M. Effects of FUT-175, a new synthetic protease inhibitor on endotoxin-induced disseminated intravascular coagulation in rats. Haemostasis 1983; 13: 374-8.
4. 4. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 1985; 15: 164-8.
5. 5. Takahashi H, Takizawa S, Tatewaki W, Nagai K, Wada K, Hanano M, Shibata A. Nafamostat mesilate (FUT-175) in the treatment of patients with disseminated intravascular coagulation. Thromb Haemost 1989; 62: 372.
6. 6. Akizawa T, Toshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate: A regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 1993; 64: 376-81.
7. 7. Tanaka K, Kondo C, Takagi I, Sato T, Yada I, Yusa H, Kusagawa M. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery. ASAIO J 1993; 39: 545.
8. 8. Kinugasa E, Akizawa T, Nakashima Y, Wakasa M, Koshikawa S. Nafamostat as anti-coagulant for membrane plasmapheresis in high bleeding risk patients. Int J Artif Organs 1992; 15: 595-600.
9. 9. Lukaszyk A, Bodzenta-Lukaszyk A, Gabryelewicz A, Bielawiec M. Blood platelet function in canine acute pancreatitis with reference to treatment with nafamostat mesilate (FUT-175). Thrombs Res 1992; 65: 229-39.
10. 10. Segal HC, Hunt BJ, Yacoub MH. The in vitro effects of aprotinin and nafamostat mesilate on whole blood impedance aggregation. Br J Haematol 1992; 80 (suppl. 1): 8.
11. 1, local anesthetics and serine protease inhibitor. Prostaglandins 1977; 14: 1075-93.
12. 12. Aoki N, Naito K, Yoshida N. Inhibition of platelet aggregation by protease inhibitors, possible involvement of protease in platelet aggregation. Blood 1978; 52: 1-12.
13. 13. Kosaki G, Nomura T, Kambayashi J. The mechanism of the inhibitory effect of proteinase inhibitors on platelet aggregation and cellular synthesis of prostaglandins. 1. The effect on the release of arachidonic acid from phospholipids. Thromb Res 1980; 20: 587-98.
14. 14. Bom GVR. Aggregation of blood platelets by ADP and its reversal. Nature 1962; 194: 927-9.
15. 15. Katsura M, Miyamoto N, Hamanaka N, Kondo K, Terada Y, Ohgaki Y. Kawasaki A, Tsuboshima M. In vitro and in vivo effects of new powerful thromboxane antagonists (3-alkylamino pinane derivatives). In: Samuelsson B, Paoletti R, Ramwell P eds, Advances in Prostaglandin, Thromboxane and Leukotriene Research. New York: Raven Press, 1983: 351-7.
16. 16. Johnson PC, Ware JA, Cliveden PB, Smith M, Dvorak AM, Salzman EW. Measurement of ionized calcium in blood platelets with the photoprotein Aequorin. Comparison with Quin 2. J Biol Chem 1985; 260: 2069-76.
17. 2 activation. Blood 1993; 81: 994-1000.
18. 2-glycoprotein-I upon the content of cAMP and cGMP in human blood platelets. Thromb Haemostas 1985; 54: 824-7.
19. 19. Valet G, Tschoepe D, Gabriel H, Valet M. Standardized, self-learning flow cytometric list mode data classifier: Classif 1 for thrombocyte and lymphocyte immune phenotyping. Ann NY Acad Sci 1993; 677: 233-51.
20. 20. Tschoepe D, Driesch E, Schwippert B, Nieuwenhuis HK. Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia. Diabetes 1995; 44: 890-4.